Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rotavirus nonstructural protein 1 (NSP1) is a critical virulence factor encoded by gene segment 5 that functions as a powerful antagonist of the host innate immune response. It primarily acts by hijacking host cellular machinery, specifically Cullin-RING ligases (CRLs), to induce the proteasomal degradation of key transcription factors such as interferon regulatory factors (IRF3, IRF5, IRF7, and IRF9) [1, 10, 13]. Additionally, in many human and porcine strains, NSP1 targets the β-transducin repeat-containing protein (β-TrCP) for degradation, thereby preventing NF-κB activation and further suppressing the production of type I and III interferons [14, 15]. Beyond interferon antagonism, NSP1 interacts with host proteins like p53 to suppress early-stage apoptosis and can degrade RNase L to subvert the OAS-RNase L antiviral pathway [11, 12]. Although NSP1 is not always essential for viral replication in vitro, its role in suppressing the host immune response makes it vital for viral spread and pathogenesis in vivo [15, 16]. Consequently, NSP1 is a significant target for the development of novel antiviral strategies and the engineering of live-attenuated vaccines. Research into inhibitors that block NSP1's ability to recruit host ligases, such as neddylation inhibitors, highlights its potential as a therapeutic target [2].
Induces proteasomal degradation of host antiviral proteins by hijacking host Cullin-RING ubiquitin ligases (CRL1 and CRL3) to act as a viral E3 ligase mimic, or inhibits targeting pathways through direct interaction with signaling proteins such as RIG-I and p53 [6, 11, 13].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-structural protein 1 (NSP1) (NSP1).